Interaction of gelatin with polyenes modulates antifungal activity and biocompatibility of electrospun fiber mats

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2439-2458

  Lakshminarayanan, Rajamani ^a,b   Sridhar, Radhakrishnan ^c   Loh, Xian Jun ^d   Nandhakumar, Muruganantham ^a   Barathi, Veluchamy Amutha ^a,e   Kalaipriya, Madhaiyan ^c   Kwan, Jia Lin ^a   Liu, Shou Ping ^a,b   Beuerman, Roger Wilmer ^a,b   Ramakrishna, Seeram ^c,f  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MATERIALS RESEARCH AND ENGINEERING   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f Department of Ophthalmology Yong Loo Lin School of Medicine National University of Singapore ^*  (Singapore)

Author keywords

Antifungals; Controlled release; Drug matrix interactions; Electrospinning; Fungal infections

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GELATIN; ITRACONAZOLE; NATAMYCIN; POLYENE; TERBINAFINE; ARTIFICIAL MEMBRANE; BIOMATERIAL; DELAYED RELEASE FORMULATION; NANOCAPSULE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; BIOCOMPATIBILITY; BIOPHYSICS; CANDIDA ALBICANS; CANDIDACIDAL ACTIVITY; CELL KINETICS; CIRCULAR DICHROISM; CONFORMATION; CONTROLLED STUDY; CORNEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ELECTROSPINNING; FIBER MATS; FIBROBLAST; FLOW KINETICS; FOOD AND DRUG ADMINISTRATION; FUNGAL KINETICS; FUNGUS GROWTH; GROWTH INHIBITION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; MECHANICS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR STABILITY; NONHUMAN; PARTICLE SIZE; SCLERA; TRIPLE HELIX; ADMINISTRATION AND DOSAGE; ARTIFICIAL MEMBRANE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG EFFECTS; DRUG POTENTIATION; ELECTROPLATING INDUSTRY; FUNGUS; PHYSIOLOGY; PROCEDURES; ROTATION;

ANTIFUNGAL AGENTS; BIOCOMPATIBLE MATERIALS; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG SYNERGISM; ELECTROPLATING; FUNGI; GELATIN; MEMBRANES, ARTIFICIAL; NANOCAPSULES; ROTATION;

EID: 84901499911     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S58487     Document Type: Article

References (58)

1. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336(6082):647.
2. Fisher MC, Henk DA, Briggs CJ, etal. Emerging fungal threats to animal, plant, and ecosystem health. Nature. 2012;484(7393):186-194.
3. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165): 165rv13.
4. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2-15.
5. Lai CC, Tan CK, Huang YT, Shao PL, Hsueh PR. Current challenges in the management of invasive fungal infections. J Infect Chemother. 2008;14(2):77-85.
6. Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol. 2005;53(6):931-951.
7. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol. 2002;38(12-13):947-957.
8. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother. 2003;47(8): 2404-2412.
9. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22(6):568-573.
10. Masia CM, Gutierrez RF. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002;2(9):550-563.
11. Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS Pathog. 2012;8(9):e1002870.
12. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov. 2010;9(9):719-727.
13. Hsu LY, Wijaya L, Shu-Ting Ng E, Gotuzzo E. Tropical fungal infections. Infect Dis Clin North Am. 2012;26(2):497-512.
14. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv. 2010;7(11):1303-1327.
15. Zumbuehl A, Ferreira L, Kuhn D, etal. Antifungal hydrogels. Proc Natl Acad Sci U S A. 2007;104(32):12994-12998.
16. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585-594.
17. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother. 2000;44(6):1463-1469.
18. Gupta M, Goyal AK, Paliwal SR, etal. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res. 2010;20(4):341-350.
19. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel system for antifungal drugs in the treatment of topical fungal disease. Indian J Exp Biol. 2009;47(5):368-375.
20. Ramos G, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother. 1999;44(2): 283-286.
21. Prabhu P, Patravale V, Joshi M. Nanocarriers for effective topical delivery of anti-infectives. Curr Nanosci. 2012;8(4):491-503.
22. Teo WE, Ramakrishna S. A review on electrospinning design and nanofiber assemblies. Nanotechnology. 2006;17(14):R89-R106.
23. Greiner A, Wendorff JH. Electrospinning: a fascinating method for the preparation of ultrathin fibers. Angew Chem Int Ed Engl. 2007;46(30):5670-5703.
24. Murugan R, Ramakrishna S. Design strategies of tissue engineering scaffolds with controlled fiber orientation. Tissue Eng. 2007;13(8): 1845-1866.
25. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater. 2004;70(2):286-296.
26. Zahedi P, Rezaeian I, Ranaei-Siadat SO, Jafari SH, Supaphol P. A review on wound dressings with an emphasis on electrospun nanofibrous polymeric bandages. Polym Adv Technol. 2010;21(2):77-95.
27. Malmsten M. Antimicrobial and antiviral hydrogels. Soft Matter. 2011;7(19):8725-8736.
28. Schiffman JD, Elimelech M. Antibacterial activity of electrospun polymer mats with incorporated narrow diameter single-walled carbon nanotubes. ACS Appl Mater Interfaces. 2011;3(2):462-468.
29. Tan K, Obendorf SK. Fabrication and evaluation of electrospun nanofibrous antimicrobial nylon 6 membranes. J Memb Sci. 2007;305(1-2):287-298.
30. Chen L, Bromberg L, Hatton TA, Rutledge GC. Electrospun cellulose acetate fibers containing chlorhexidine as a bactericide. Polymer. 2008;49(5):1266-1275.
31. Taepaiboon P, Rungsardthong U, Supaphol P. Vitamin-loaded electrospun cellulose acetate nanofiber mats as transdermal and dermal therapeutic agents of vitamin A acid and vitamin E. Eur J Pharm Biopharm. 2007;67(2):387-397.
32. Ignatova M, Stoilova O, Manolova N, Markova N, Rashkov I. Electrospun mats from styrene/maleic anhydride copolymers: modification with amines and assessment of antimicrobial activity. Macromol Biosci. 2010;10(8):944-954.
33. Bshena O, Heunis TD, Dicks LM, Klumperman B. Antimicrobial fibers: therapeutic possibilities and recent advances. Future Med Chem. 2011;3(14):1821-1847.
34. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater. 2004;71(2): 343-354.
35. Liu X, Smith LA, Hu J, Ma PX. Biomimetic nanofibrous gelatin/apatite composite scaffolds for bone tissue engineering. Biomaterials. 2009;30(12):2252-2258.
36. Choktaweesap N, Arayanarakul K, Aht-ong D, Meechaisue C, Supaphol P. Electrospun gelatin fibers: effect of solvent system on morphology of and fiber diameters. Polym J. 2007;39:622-631.
37. Oren Z, Shai Y. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study. Biochemistry. 1997;36(7):1826-1835.
38. Ignatova M, Rashkov I, Manolova N. Drug-loaded electrospun materials in wound-dressing applications and in local cancer treatment. Expert Opin Drug Deliv. 2013;10(4):469-483.
39. Xu P, Huang J, Cebe P, Kaplan DL. Osteogenesis imperfecta collagen-like peptides: self-assembly and mineralization on surfaces. Biomacromolecules. 2008;9(6):1551-1557.
40. Beck K, Chan VC, Shenoy N, Kirkpatrick A, Ramshaw JA, Brodsky B. Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine. Proc Natl Acad Sci U S A. 2000;97(8):4273-4278.
41. Fujitsu M, Hattori M, Tamura T. Effects of hydroxy compounds on gel formation of gelatin. Colloid Polym Sci. 1997;275(1):67-72.
42. Xu K, Nowak I, Kirchner M, Xu Y. Recombinant collagen studies link the severe conformational changes induced by osteogenesis imperfecta mutations to the disruption of a set of interchain salt bridges. J Biol Chem. 2008;283(49):34337-34344.
43. Li Y, Foss CA, Summerfield DD, etal. Targeting collagen strands by photo-triggered triple-helix hybridization. Proc Natl Acad Sci U S A. 2012;109(37):14767-14772.
44. Gekko K, Li X, Makino S. Effects of polyols and sugars on the sol-gel transition of gelatin. Biosci Biotech Biochem. 1992;56(8):1279-1284.
45. Vandermeulen G, Rouxhet L, Arien A, Brewster ME, Preat V. Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(ε-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int J Pharm. 2006;309(1-2):234-240.
46. Bang JY, Song CE, Kim C, etal. Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)/dextran graft copolymer. Arch Pharm Res. 2008;31(11): 1463-1469.
47. Egito LC, de Medeiros SR, Medeiros MG, Price JC, Egito ES. Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential. J Pharm Sci. 2004;93(6):1557-1565.
48. Balakrishnan AR, Easwaran KR. CD and NMR studies on the aggregation of amphotericin-B in solution. Biochim Biophys Acta. 1993;1148(2):269-277.
49. Barwicz J, Tancrede P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol-or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids. 1997;85(2):145-155.
50. Huang W, Zhang Z, Han X, etal. Ion channel behavior of amphotericin B in sterol-free and cholesterol-or ergosterol-containing supported phosphatidylcholine bilayer model membranes investigated by electrochemistry and spectroscopy. Biophys J. 2002;83(6): 3245-3255.
51. Puttipipatkhachorn S, Nunthanid J, Yamamoto K, Peck GE. Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. J Control Release. 2001;75(1-2):143-153.
52. Kai D, Jin G, Prabhakaran MP, Ramakrishna S. Electrospun synthetic and natural nanofibers for regenerative medicine and stem cells. Biotechnol J. 2013;8(1):59-72.
53. Loh XJ, Gong J, Sakuragi M, etal. Surface coating with a thermoresponsive copolymer for the culture and non-enzymatic recovery of mouse embryonic stem cells. Macromol Biosci. 2009;9(11):1069-1079.
54. Loh XJ, Peh P, Liao S, Sng C, Li J. Controlled drug release from biodegradable thermoresponsive physical hydrogel nanofibers. J Control Release. 2010;143(2):175-182.
55. Appel EA, del Barrio J, Loh XJ, Scherman OA. Supramolecular polymeric hydrogels. Chem Soc Rev. 2012;41(18):6195-6214.
56. Ye EY, Loh XJ. Polymeric hydrogels and nanoparticles: a merging and emerging field. Aust J Chem. 2013;66(9):997-1007.
57. Appel EA, Loh XJ, Jones ST, Dreiss CA, Scherman OA. Sustained release of proteins from high water content supramolecular polymer hydrogels. Biomaterials. 2012;33(18):4646-4652.
58. Appel EA, Loh XJ, Jones ST, Biedermann F, Dreiss CA, Scherman OA. Ultrahigh-water-content supramolecular hydrogels exhibiting multistimuli responsiveness. J Am Chem Soc. 2012;134(28):11767-11773.